• Western blot analysis of extracts of Rat liver, using CYP3A4 antibody (STJ115445) at 1:1000 dilution. Secondary antibody: HRP Goat Anti-rabbit IgG (H+L) at 1:10000 dilution. Lysates/proteins: 25ug per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Basic Kit. Exposure time: 15s.
  • Western blot analysis of extracts from normal (control) and CYP3A4 rabbit polyclonal antibody knockout (KO) 293T cells, using CYP3A4 rabbit polyclonal antibody antibody (STJ115445) at 1:1000 dilution. Secondary antibody: HRP Goat Anti-rabbit IgG (H+L) at 1:10000 dilution. Lysates/proteins: 25ug per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Basic Kit. Exposure time: 30s.

Anti-CYP3A4 antibody (244-503) (STJ115445)

SKU:
STJ115445

Shipping:
Free Shipping
Current Stock:
Host: Rabbit
Applications: WB
Reactivity: Human/Mouse/Rat
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Rabbit polyclonal antibody anti-CYP3A4 (244-503) is suitable for use in Western Blot research applications.
Clonality: Polyclonal
Conjugation: Unconjugated
Isotype: IgG
Formulation: PBS with 0.02% Sodium Azide, 50% Glycerol, pH7.3.
Purification: Affinity purification
Dilution Range: WB 1:500-1:1000
Storage Instruction: Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles.
Gene Symbol: CYP3A4
Gene ID: 1576
Uniprot ID: CP3A4_HUMAN
Immunogen Region: 244-503
Immunogen: Recombinant fusion protein containing a sequence corresponding to amino acids 244-503 of human CYP3A4 (NP_059488.2).
Immunogen Sequence: EVTNFLRKSVKRMKESRLED TQKHRVDFLQLMIDSQNSKE TESHKALSDLELVAQSIIFI FAGYETTSSVLSFIMYELAT HPDVQQKLQEEIDAVLPNKA PPTYDTVLQMEYLDMVVNET LRLFPIAMRLERVCKKDVEI NGMFIPKGVVVMIPSYALHR DPKYWTEPEKFLPERFSKKN KDNIDPYIYTPFGSGPRNCI GMRFALMNMKLALIRVLQNF SFKPCKETQIPLKLSLGGL
Tissue Specificity Expressed in prostate and liver. According to some authors, it is not expressed in brain. According to others, weak levels of expression are measured in some brain locations. Also expressed in epithelium of the small intestine and large intestine, bile duct, nasal mucosa, kidney, adrenal cortex, epithelium of the gastric mucosa with intestinal metaplasia, gallbladder, intercalated ducts of the pancreas, chief cells of the parathyroid and the corpus luteum of the ovary (at protein level).
Post Translational Modifications Polyubiquitinated in the presence of AMFR and UBE2G1 and also STUB1/CHIP and UBE2D1 (in vitro).
Function A cytochrome P450 monooxygenase involved in the metabolism of sterols, steroid hormones, retinoids and fatty acids. Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase). Catalyzes the hydroxylation of carbon-hydrogen bonds. Exhibits high catalytic activity for the formation of hydroxyestrogens from estrone (E1) and 17beta-estradiol (E2), namely 2-hydroxy E1 and E2, as well as D-ring hydroxylated E1 and E2 at the C-16 position. Plays a role in the metabolism of androgens, particularly in oxidative deactivation of testosterone. Metabolizes testosterone to less biologically active 2beta- and 6beta-hydroxytestosterones. Contributes to the formation of hydroxycholesterols (oxysterols), particularly A-ring hydroxylated cholesterol at the C-4beta position, and side chain hydroxylated cholesterol at the C-25 position, likely contributing to cholesterol degradation and bile acid biosynthesis. Catalyzes bisallylic hydroxylation of polyunsaturated fatty acids (PUFA). Catalyzes the epoxidation of double bonds of PUFA with a preference for the last double bond. Metabolizes endocannabinoid arachidonoylethanolamide (anandamide) to 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid ethanolamides (EpETrE-EAs), potentially modulating endocannabinoid system signaling. Plays a role in the metabolism of retinoids. Displays high catalytic activity for oxidation of all-trans-retinol to all-trans-retinal, a rate-limiting step for the biosynthesis of all-trans-retinoic acid (atRA). Further metabolizes atRA toward 4-hydroxyretinoate and may play a role in hepatic atRA clearance. Responsible for oxidative metabolism of xenobiotics. Acts as a 2-exo-monooxygenase for plant lipid 1,8-cineole (eucalyptol). Metabolizes the majority of the administered drugs. Catalyzes sulfoxidation of the anthelmintics albendazole and fenbendazole. Hydroxylates antimalarial drug quinine. Acts as a 1,4-cineole 2-exo-monooxygenase. Also involved in vitamin D catabolism and calcium homeostasis. Catalyzes the inactivation of the active hormone calcitriol (1-alpha,25-dihydroxyvitamin D(3)).
Protein Name Cytochrome P450 3a4
1 -4-Cineole 2-Exo-Monooxygenase
1 -8-Cineole 2-Exo-Monooxygenase
Albendazole Monooxygenase
Sulfoxide-Forming
Albendazole Sulfoxidase
Cypiiia3
Cypiiia4
Cholesterol 25-Hydroxylase
Cytochrome P450 3a3
Cytochrome P450 Hlp
Cytochrome P450 Nf-25
Cytochrome P450-Pcn1
Nifedipine Oxidase
Quinine 3-Monooxygenase
Database Links Reactome: R-HSA-211945
Reactome: R-HSA-211981
Reactome: R-HSA-5423646
Reactome: R-HSA-9027307
Reactome: R-HSA-9749641
Reactome: R-HSA-9754706
Reactome: R-HSA-9757110
Cellular Localisation Endoplasmic Reticulum Membrane
Single-Pass Membrane Protein
Microsome Membrane
Alternative Antibody Names Anti-Cytochrome P450 3a4 antibody
Anti-1 -4-Cineole 2-Exo-Monooxygenase antibody
Anti-1 -8-Cineole 2-Exo-Monooxygenase antibody
Anti-Albendazole Monooxygenase antibody
Anti-Sulfoxide-Forming antibody
Anti-Albendazole Sulfoxidase antibody
Anti-Cypiiia3 antibody
Anti-Cypiiia4 antibody
Anti-Cholesterol 25-Hydroxylase antibody
Anti-Cytochrome P450 3a3 antibody
Anti-Cytochrome P450 Hlp antibody
Anti-Cytochrome P450 Nf-25 antibody
Anti-Cytochrome P450-Pcn1 antibody
Anti-Nifedipine Oxidase antibody
Anti-Quinine 3-Monooxygenase antibody
Anti-CYP3A4 antibody
Anti-CYP3A3 antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance